October 12-15, 2026 | www.worldadc-usa.com

17th ANNUAL WORLD adc SAN DIEGO 2026

Redefining Early-Line Oncology Patient Impact

Solidifying ADCs as Standard of Care Therapies by De-Risking Differentiated Payload MoAs Beyond Topo1, Elevating ADCs to Deliver Wider Impact in the Clinical Landscape & Adapting Manufacturing Efficiency for Novel & Cost-Effective ADCs

- 1,300+ INDUSTRY ATTENDEES
- 400+ COMPANIES IN THE ROOM
- 4 DAYS OF EXCLUSIVE INSIGHTS
- 7 TRACKS OF END-TO-END CONTENT
- 1 UNMISSABLE ADC EVENT

PRELIMINARY AGENDA:
FULL PROGRAM TO BE RELEASED IN JUNE

170+ World-Class Speakers Include:

Suzanne Edavettal
Vice President, Research & Head, Protein Therapeutics

Vinod Bulusu
Executive Director, Product Stewardship Lead

Giorgia Vicentini
Vice President, Global Program Lead, Oncology

Ronald Fleming
Executive Director, Clinical Development

Gail Lewis
Distinguished Scientist, Discovery Oncology

Bob Lutz
Chief Scientific Officer

Jeffrey Settleman
Chief Scientific Officer, Oncology R&D

Dominik Schumacher
Chief Executive Officer

Rita Nanda
Associate Professor, Medicine & Director, Breast Oncology, Section of Hematology/Oncology

Lead Partner: XDC The Bioconjugation Leader

Senior Partners: ABZENA Moving medicine forward. | Ajinomoto | BIO•PHARMA SERVICES | cytiva | VERANOVA

REGISTER NOW

Advancing Differentiated ADCs to Redefine Early-Line Oncology Patient Outcomes

With groundbreaking readouts and approvals into first-line metastatic indications and ambitions set on early-stage, neoadjuvant settings, **ADCs are solidifying themselves as the modality that will redefine the standard of care across oncology and beyond**.

In the age of Topo1 saturation and threat of patient resistance, biopharma is investing heavily in novel mechanisms, targets, and bioconjugate design. With the new era of ADCs starting to enter the clinic and attract dealmaking attention, the ADC field is evolving to **unlock the next wave of ADC innovation and secure an effective therapeutic landscape for patients in need**.

Returning as the definitive ADC industry orientation point, the **17th World ADC San Diego** is *THE* one-stop bioconjugate shop for anyone interested in, starting out, or actively working on ADCs. Join over 1,300 industry enthusiasts from biopharma, innovative start-ups, leading service providers and academic, physician and regulator KOLs for an unparalleled global amalgamation of case studies, development trends and networking opportunities to **forge ADC innovation into differentiated, early-line patient outcomes**.

With 7 streams of end-to-end ADC content across **Discovery Chemistry**, **Discovery Biology**, **Preclinical**, **Translational Medicine**, **Clinical Lessons**, **Process & Analytical Development**, and **Manufacturing & Supply Chain**, all the ADC innovation will be in the spotlight for an unmissable week of data and insights to de-risk future ADC development and **redefine the precision oncology therapeutic landscape**.

Whether you are exploring the field or have over a decade of experience, attending to understand the fundamentals, stay up to date with scientific trends, or network to establish new business relationships – **World ADC San Diego** is the place to be to discuss, debate and advance the future of ADC development.

World ADC Team

New Industry-Leading Insights in 2026

First-Time ADC Research & Clinical Data Disclosures:

- AstraZeneca: **PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency**
- KIVU BIOSCIENCE: **Spotlighting the Translational Profile of KIVU-107 to Strive for Kinder & Gentler ADC Therapies with Enhanced Therapeutic Index**
- MacroGenics: **Characterizing Containment Bags as a Development Tool in ADC Lyophilization**
- SUTRO BIOPHARMA: **Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Link Enhanced Design to Differentiated ADC Clinical Performance**

New Companies Making Their World ADC Presentation Debut:

Dual Payload Innovation & Translation

callio THERAPEUTICS

CANWELL

Enhanced ADC Chemistry & Mechanism

MediLink Therapeutics

Bispecific ADC & Novel Target Characterization

NEOK BIO

SOLVE THERAPEUTICS

XYone Therapeutics

ADC Speed to the Clinic

Immunome

Upgraded Clinical Content to Unlock ADC Differentiation:

Expanded ADC Clinician Perspectives

Exploring "ADC + Antibody" as an Emerging Combination Strategy for Solid Tumor Therapies

Peng Guo, Hangzhou Institute of Medicine

Evaluating I-SPY2 Clinical Data & Toxicity Monitoring to Assess ADC Progression to Early-Stage Oncology Settings in TNBC & HER2+ Breast Cancer

Rita Nanda, University of Chicago

Elevated Industry ADC Clinical Strategy

Spotlighting the Clinical Profile & Positioning of IKS014 to Contextualize ADC Sequencing

Jutta Deckert, Iksuda Therapeutics

Setting the Scene for Novel Combination Partner Approaches for Vedotin-Based ADCs Including Padcev

Sujata Narayanen, Pfizer

REGISTER BEFORE FRIDAY, JUNE 5 & SAVE UP TO $700

CONTENTS

REGISTER NOW

Contextualizing Cutting-Edge ADC Insights in an Evolving Global Landscape

The need for differentiation is not a new challenge for the ADC community, with 2026 demonstrating increased research, investment and dealmaking towards non-traditional ADCs across bispecific and dual payload ADCs, DACs, AOCs, ISACs and beyond:

23% 10-Year CAGR of non-traditional ADC unique patent families published versus 11% for traditional ADCs

99% Annual Growth in the number of non-traditional ADCs between Jan 2025 - Feb 2026, with **595 ADCs identified**

Novel Conjugate Published Patent Applications Per Year



**Data provided by Beacon by Hanson Wade. Correct as of April 2026.*

April 2026: *Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs*

April 2026: *CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload ADCs*

April 2026: *Roche dips into DACs with existing partner C4 Therapeutics for $20M upfront*

Spotlighting Top Innovation & Bottlenecks to Secure Early-Line ADC Patient Impact

Leveraging Novel Payload Mechanisms & Combinations to Circumvent Patient Resistance:

- Showcasing Non-Cytotoxic Payload Attributes, Selection & Performance to Enhance ADC Therapeutic Index Beyond the Cytotoxic Dogma — Genentech
- Exploring Development of E7766-Based STING ADCs: Influence of Payload Linker Attachment Site & Cleavage Kinetics — Eisai
- Pan-RASi ADCs: Spotlighting Optimization of RAS-Inhibitor Payloads to Differentiate ADC Mechanism Beyond Topo1 — zymeworks

Upgrading the Preclinical Toolbox to Translate Traditional & Novel ADCs with Confidence:

- Spotlighting Comprehensive Preclinical Development of Antifolate ADCs to Enter IND Phase for a Novel Drug-Linker Mechanism — byondis
- The Emerging Wave of Bispecific ADCs: Breaking Down Design & Rationale for NEOK001 & NEOK002 — NEOK BIO
- Breaking Down Preclinical Characterization of STRO-227 Dual Payload ADC to Evaluate Efficacy & Safety in ADC Resistance Models — SUTRO BIOPHARMA

Navigating Crowded Clinical Indications to Achieve ADC Differentiation & Maximize Patient Benefit:

- Reviewing the Intentional Design of Varseta-M, a Masked PROBODY ADC for the Treatment of Colorectal Cancer — CytomX Therapeutics
- Contextualizing Clinical Success of Enhertu Combination to Secure First-Line Approval in HER2+ Metastatic Breast Cancer — Daiichi-Sankyo
- Analyzing 5T4-Targeted JK06 Phase I/II Expansion Cohort Data: Leveraging Biparatopic & Conjugation Design to Unlock a Novel Activity & Safety Profile — SalubrisBio

Enhancing Bioconjugate Characterization & Production to Manufacture Cost-Effective ADCs at Scale:

- Showcasing Capability & Application of Automated HLPC to Undergo ADC Process Development Optimization — Bristol Myers Squibb
- Beyond Traditional ADCs: Breaking Down Control Strategies for Non-Cytotoxic Bioconjugate Modalities — IQ
- Breaking Down Case Study Learnings to Optimize Outsourced Bioconjugation & Minimize ADC Production Cost & Timelines — Takeda

Agenda at a Glance

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

Seminar Day
Monday, October 12

- Introduction to ADCs Day
- 4th Novel Conjugates Day
- 3rd Pharmacology Day
- 7th Toxicity Day
- 10th ADCs in Combination Day
- 2nd Analytical & CQA Day
- 8th CMC Day

Lunch & Networking

- Introduction to ADCs Day
- 4th Novel Conjugates Day
- 3rd Pharmacology Day
- 7th Toxicity Day
- 10th ADCs in Combination Day
- 2nd Analytical & CQA Day
- 8th CMC Day

Ambassador's Reception
Hosted By: ABZENA Moving medicine forward.

Scientific Program Day One
Tuesday, October 13

Striving for the Next Wave of ADC Innovation: Contextualizing Novel ADC Mechanism & Design Validation to De-Risk Future ADC Development & Deliver Differentiated Patient Benefit

Morning Break & Networking

- Discovery Chemistry
- Discovery Biology
- Preclinical
- Translational Medicine
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Lunch & Networking

- Discovery Chemistry
- Discovery Biology
- Preclinical
- Translational Medicine
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Afternoon Break & Networking

Demonstrating the Transformative Impact of ADCs to Reshape the Standard of Oncology Care & Deliver Improved Therapeutic Outcomes for Patients in Early-Line Settings

Drinks Reception

Scientific Program Day Two
Wednesday, October 14

Beyond the Topo1 Dogma: Unveiling Rationale-Driven Novel Payload Development & Properties to Herald ADCs with New Mechanisms & Improved Therapeutic Index

Morning Break & Networking

- Discovery Chemistry
- Discovery Biology
- Preclinical
- Translational Medicine
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Lunch & Networking

- Discovery Chemistry
- Discovery Biology
- Preclinical
- Translational Medicine
- Clinical Lessons
- Process & Analytical Development
- Manufacturing & Supply Chain

Afternoon Break & Networking

Delving Into ADC Performance in Crowded Clinical Indications With Approved ADC Therapies to Understand How Differences in Biconjugate Design & Clinical Strategy Correlates to Patient Impact

13th Annual ADC Awards

Workshop Day
Thursday, October 15

Pick One Morning Workshop

- **Workshop A** - Immune-Modulating ADCs
- **Workshop B** – ADC Toxicity Prediction
- **Workshop C** – ADC Design Strategy
- **Workshop D** – ADC Bioanalysis & PK/PD
- **Workshop E** – CMC Stakeholder Management

Lunch & Networking

Pick One Afternoon Workshop

- **Workshop F** – Linker & Conjugation Deep-Dive
- **Workshop G** – Optimizing ADC Translation
- **Workshop H** – ADC Clinical Differentiation
- **Workshop I** – Novel Conjugate Control Strategy
- **Workshop J** – ADC CMC: From Gene to IND

REGISTER BEFORE FRIDAY, JUNE 5 & SAVE UP TO $700

CONTENTS

REGISTER NOW

Built-In, Dedicated ADC Networking:

Scientific Poster Session

Tuesday & Wednesday | All Day

As a permanent feature in the Exhibition Hall, leverage the Scientific Poster Session to showcase your ADC research with attendees and discover new insights from your peers. One poster will be selected as the 'Best Poster' winner at the World ADC Awards!

Submissions Opening Soon



Meeting Booking & Networking Tool

Tuesday & Wednesday | All Day

Make the most of the Event App to connect and schedule meetings with the best and brightest in ADC development during Scientific Program Day One & Day Two, with a dedicated meeting zone to engage face-to-face and forge new connections.

Exhibition Booth Networking

Tuesday & Wednesday | All Day

Make the most of face-to-face interactions to explore and engage booths across the A-Z of expert ADC partners to ask questions, see demonstrations, and exchange business cards with prospective technology and service providers.

13th World ADC Awards

Wednesday | After Conference Program

The climactic finale of the second main conference day. Celebrate and recognize long-term contributors, novel and innovative programs, and upcoming pioneers who have gone above and beyond to ensure the continued success of the field.

Submissions Opening Soon

Evening Ambassador's & Drinks Reception

Monday & Tuesday | After Conference Program

With a backdrop of palm trees and the San Diego sunset, enjoy a drink of your choice, reconnect with peers, and meet fresh faces to continue and develop your ADC learnings and objectives.

2025 Networking in Numbers:

With the global ADC community reunited under one roof, don't miss the 17+ hours of unrivaled networking opportunities that World ADC San Diego has to offer:

400+
Pharma, biotech, service provider & NFP companies under one roof

38%
North American ADC biotechs in the room*

735
Private meetings scheduled with 12% adoption rate

**According to companies identified by Beacon by Hanson Wade*

World-Class Speaker Faculty Early Release

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

Jack Chen
Scientific Director, Translational Oncology, Precision Medicine
AbbVie

Suzanne Edavettal
Vice President, Research & Head, Protein Therapeutics
Amgen

Herbert Ogutu
Senior Manager, Contract Development & Manufacturing
Amgen

Vinod Bulusu
Executive Director, Product Stewardship Lead
AstraZeneca

Alyn Davies
Associate Director, Medicinal Chemistry
AstraZeneca

Malini Iyer
Associate Director, Oncology Safety & Discovery
AstraZeneca

Seb Caille
Senior Director, AOC Process Development
Avidity Biosciences, a Novartis Company

L. Nathan Tumey
Associate Professor
Binghampton University

Jian Chen
Director, Translational Research & Preclinical Development
BioAtla

David Bramhill
President & Founder
Bramhill Biologics Consulting

Giorgia Vicentini
Vice President, Global Program Lead, Oncology
Bristol Myers Squibb

Hui Wei
Chair, Biologics Specification Committee & Head, Biologics Analytical Technical Integration
Bristol Myers Squibb

Wim Dokter
Chief Scientific Officer
Byondis

Jerome Boyd-Kirkup
Chief Scientific Officer
Callio Therapeutics
NEW COMPANY

Henry Yu
Chief Executive Officer
CanWell Pharma
NEW COMPANY

Sean McCarthy
Chief Executive Officer
CytomX Therapeutics

Ronald Fleming
Executive Director, Clinical Development
Daiichi Sankyo

Kohei Takano
Scientist, Discovery Research
Daiichi Sankyo

Dae-Shik Kim
Senior Principal Scientist
Eisai

Jianxin Guo
Director, Regulatory CMC Biotechnology
Eli Lilly & Company

Jonathan Harris
Executive Director, Regulatory Affairs CMC
Exelixis

Gail Lewis
Distinguished Scientist, Discovery Oncology
Genentech

Bingchuan Wei
Senior Principal Scientist, CMC Team Lead
Genentech

Matthew Lorenz
Director, Bio Pivotal Analytical Development
Gilead Sciences

CONTENTS

World-Class Speaker Faculty Early Release

Melissa Schutten
Executive Director, Nonclinical Sciences & Pathology
Gilead Sciences

Peng Guo
Professor & Principal Investigator
Hangzhou Institute of Medicine

Jutta Deckert
Vice President, R&D
Iksuda Therapeutics

Bob Lutz
Chief Scientific Officer
Iksuda Therapeutics

Min Hu
Senior Vice President, Discovery
Innovent Biologics

Mo Trikha
Chief Executive Officer
Kivu Biosciences

Aaron Pruett
Principal Scientist, Drug Product Sciences
MacroGenics

Jiaqiang Cai
Co-Founder & Chief Scientific Officer
MediLink Therapeutics
NEW COMPANY

Paritosh Pande
Associate Principal Scientist, Sterile Drug Product Commercialization
Merck & Co.

Patrick Zweidler-McKay
Chief Medical Officer
NEOK Bio
NEW COMPANY

Ya-Chi Chen
Chief Scientific Officer
OBI Pharma

Christian Rohlff
Chief Executive Officer
Oxford BioTherapeutics

Sujata Narayanen
Vice President, Global Development Product Lead
Pfizer

Scott Peterson
Head, ADC Discovery
Pfizer

Jeffrey Settleman
Chief Scientific Officer, Oncology R&D
Pfizer

John Lambert
Independent Consultant & Honorary Professor
Queens University Belfast

Wenhua Wang
Fellow Scientist
Regeneron

Hao Liu
Senior Director, Drug Discovery & Cancer Biology
Solve Therapeutics
NEW COMPANY

Hanspeter Gerber
Chief Scientific Officer
Sutro Biopharma

Olga Paley
Director & Head, US Downstream Process Development & Bioconjugation
Takeda

Dominik Schumacher
Chief Executive Officer
Tubulis

Niomi Peckham
Director, Pipeline Development, Global Biologics
United States Pharmacopeia
NEW COMPANY

Rita Nanda
Associate Professor, Medicine & Director, Breast Oncology Program
University of Chicago

Greg Thurber
Professor, Chemical & Biomedical Engineering
University of Michigan

Pre-Conference Seminar Day | Monday, October 12

Introduction to ADCs Day

If you're a new entrant to the ADC field, join the introductory 101 day to brush up on your ADC knowledge ahead of the main scientific program.

As more companies enter the ever-growing antibody-drug conjugate field, this seminar day will provide you with the critical knowledge gained over years of research that's culminated in the presently approved ADCs and booming innovation in the field. Led by long-standing experts and KOLs, join this one-stop-shop of ADC learning to establish a core understanding of the essential elements in ADC discovery and early development.

David Bramhill
President & Founder
Bramhill Biologics Consulting

John Lambert
Independent Consultant & Honorary Professor
Queens University Belfast

Morning session focus areas include:

- Gaining familiarity with the fundamental early learnings that inform ADC design
- Learning about the key insights that allowed early investigators to overcome the initial challenges that hindered early ADC programs
- Evaluating payload choices for ADCs
- Reviewing linker design chemistry and what it can bring
- Understanding the impact of conjugation site selection on ADCs

Lunch & Networking

Afternoon session key learning objectives:

- Gaining an understanding of the biological aspects of ADCs
- Selecting the most appropriate ADC target
- Choosing an optimum antibody format
- Analyzing the choices and trade-offs in utilizing the chemistry ADC toolbox
- Assessing key factors in the evaluation of efficacy information from *in vivo* preclinical models

End of Introduction to ADCs Day

"Being new to the field, it was an amazing experience. The seminar day was fantastic to lay the baseline of what everybody was talking about the following two days"

Merck KGaA

"The pre-conference seminar day was great because it was very focused on specific topics. The quality of the presentations and the attendees were stellar"

Quantum-Si

Pre-Conference Seminar Day | Monday, October 12

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

4th Novel Conjugates Day	3rd Pharmacology Day	7th Toxicity Day	10th ADCs in Combination Day	2nd Analytical & CQA Day	8th CMC Day
Pushing the Boundary of Novel Bioconjugate Mechanisms & Design	Accelerating the Next Wave of Tumor-Targeting Mechanisms & Behavior	Predicting, Characterizing & Mitigating ADC Toxicities to Widen Therapeutic Index	Unlocking the Therapeutic Power of Rationale-Driven ADC Combinations	Elevating Confident Characterization of Increasingly Complex Conjugates	Manufacturing Cost Efficient & Regulatory Compliant ADCs at Scale
Raising the DAR: Spotlighting Design & Preclinical Profiles of High DAR & Multi-Payload Conjugates	**Understanding the PD Profiles of Masked Payload & Dual Payload ADCs to Assess Benefit Against Traditional Therapies**	**Expanding the ADC Preclinical Toolbox to Improve Translation of ADC Toxicities to the Clinic**	**Leveraging the Power of Clinical Combinations to Elevate ADC Patient Impact in Early-Line Oncology Treatment Regiments**	**Setting the Scene for ADC CQAs & Understanding Best Approaches to Ensure Product Quality Through Robust Control Strategies**	**Leveraging Sponsor-Regulator Interactions & Feedback to Best Meet ADC Regulatory Expectations**
Investigating the Potential of Alternative Payload Mechanisms to Advance Beyond Pan-Cytotoxic ADC Therapies	**Carrying Out Thorough Pharmacology Studies to Understand & Model ADC Mechanisms & Behavior**	**Analyzing Translational Profiles of ADCs Leveraging Rationale-Driven Design to Improve Tolerability & Widen Therapeutic Index**	**Harnessing the Ability of Dual Payload & Combination Therapies to Combat Resistance Mechanisms & Improve Clinical Impact**	**Preparing for the Next Wave: What Analytical Considerations Need to Be Made for Increasingly Complex Conjugates?**	**Navigating DS & DP CMC & Formulation Intricacies to Streamline Late-Stage ADC Manufacturing**
Stretching the Limits of Traditional ADC Design: Combining Payload & Antibody Innovation on One ADC	**Highlighting Early Characterization & PD Modeling to De-Risk Preclinical Characterization of Novel ADC Payloads & Design**	**Incorporating the Physician Voice to Understand Mitigation Strategies & Experiences with Clinical Adverse Events**	**Laying Out Principles of ADC Combination Parter Selection & Design to Approach Translation with Confidence**	**Delving Into Best Practices to Confidently Characterize ADC Structural & Physicochemical Properties**	**Commercial ADC Manufacturing: Undergoing Process Scale Up & Technology Transfer Without Impacting Product Quality**
Presentation Preview:	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**
Best of Both Worlds? Spotlighting Discovery of Bispecific, Dual Payload ADC OBI-221: 2 + 2 = Innovation • Exploring rationale and design of OBI-221, a dual payload bispecific ADC targeting cMET/HER3 • Outlining lessons learned from pursuing a two hit, two target approach to guide future ADC innovation opportunities • Evaluating initial characterization of OBI-221, contextualized with early clinical performance of TROP2 ADC leveraging same design principles **Ya-Chi Chen**, Chief Scientific Officer, **OBI Pharma**	**Assessing the Mechanism & PD Characterization of Conditionally Active Biologics Leveraging the TME to Improve ADC Therapeutic Index** • Highlighting the benefits and potential of conditionally activated ADCs against traditional conjugate design • Exploring Conditionally Active Biologic mechanism leveraging tumor pH and physiological conditions for ADC activation • Spotlighting PD profiles of conditionally active ADCs to demonstrate improved therapeutic index **Jian Chen**, Director, Translational Research & Preclinical Development, **BioAtla**	**Evaluating Strategies to Assess Safety Profile of Novel ADC Payloads Under Accelerated Platform Development** • Understanding strategies to accelerate development cycle for novel ADC linker-payloads • Defining the importance of safety profiles of novel payloads, contextualized through assessment of free payload versus ADC tolerability comparison • Evaluating *in vitro* assays to employ for early payload safety profiling leading up to *in vivo* studies **Malini Iyer**, Associate Director, Oncology Safety & Discovery, **AstraZeneca**	**Utilizing Immune System Interactions & Fc Effector Function Analysis to Rationally Select Optimum ADC Combination Partners** • Leveraging understanding of ADC - immune system interactions to unlock clinically relevant checkpoint inhibitor combinations • What are other rationale-driven ADC combination partners in the immune-oncology field? • Deep diving into preclinical Fc effect function to interpret role played in ADC combinations, contextualized with Fc silent versus wild type clinical readouts **Greg Thurber**, Professor, Chemical & Biomedical Engineering, **University of Michigan**	**Evaluating Impurity Qualification Requirements for Drug-Linkers Related Impurities Used to Generate ADCs** • Evaluating conjugatable impurities in ADC drug-linkers for potential toxicological risks • Drug-linker conjugatable impurities present at ≤1.0% weight/weightare unlikely to pose a risk to patients • Contextualizing how data provides science-based justification to increase qualification limit from 0.15% to 1.0% weight/weightfor DL intermediates **Sarah Shi**, Director, Global Regulatory Affairs CMC, **BeOne Medicines**	**Leveraging Novel Process & Technology Options to Optimize Vial Fogging Challenges in ADC DP Manufacturing** • Highlighting the importance of optimizing container selection and process levers to optimize ADC DP lyophilization • Optimizing ADC DP manufacturing process to reduce challenges with vial fogging through hydrophobic vial technology • Showcasing learnings within ADC manufacturing control strategy **Paritosh Pande**, Associate Principal Scientist, Sterile Drug Product Commercialization, **Merck & Co.**

Ambassador's Reception Hosted By

The first exclusive networking event at World ADC San Diego. Under the California sunshine, this invitation-only, informal reception is your perfect opportunity to reunite with old friends and meet new colleagues ahead of the main conference days.

ABZENA
Moving medicine forward.

CONTENTS

Scientific Program Day One | Tuesday, October 13

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

7:00 Check In, Morning Coffee & Light Refreshments

7:55 **Chair's Opening Remarks**

Bob Lutz
Chief Scientific Officer
Iksuda Therapeutics

Striving for the Next Wave of ADC Innovation: Contextualizing Novel ADC Mechanism & Design Validation to De-Risk Future ADC Development & Deliver Differentiated Patient Benefit

8:00 **Panel Discussion: Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact**

- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities

Moderator:

Jeffrey Settleman
Chief Scientific Officer, Oncology R&D
Pfizer

Suzanne Edavettal
Vice President, Research & Head, Protein Therapeutics
Amgen

Bob Lutz
Chief Scientific Officer
Iksuda Therapeutics

Min Hu
Senior Vice President, Discovery
Innovent Biologics

Scott Peterson
Head, ADC Discovery
Pfizer

9:00 **WuXiDARx™ Conjugation Technology & Proprietary Payload-Linker Platform: A Powerful Alliance for Next-Generation Dual Payload ADC Development**

- Advancing next-generation dual-payload ADCs to address traditional challenges like drug resistance and narrow therapeutic windows
- Leveraging WuXiDARx™ technology for flexible DAR1-6 and WuXiTecan2™ hydrophilic linker, enabling streamlined dual-payload construction without antibody engineering
- Demonstrating a substantially wider therapeutic index alongside significantly enhanced anti-tumor efficacy in proof-of-concept studies

Marie Zhu
Chief Technology Officer
WuXi XDC

9:30 **Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design & Preclinical Characterization Links to Differentiated ADC Clinical Performance**

- Laying out the development and vision of STRO-004 leveraging enhanced antibody engineering and linker-payload design to translate into impactful clinical performance against existing ADC therapies
- Exploring brand-new Phase I clinical safety and PK data targeting Tissue Factor, contextualized with how well STRO-004 translated from cyno monkey preclinical data, to understand ADC clinical benefit and enhanced therapeutic index
- Highlighting rationale, development and the power of dual payload ADCs to subvert patient resistance mechanisms to single payload ADCs

Hanspeter Gerber
Chief Scientific Officer
Sutro Biopharma
NEW DATA

10:00 Morning Break & Structured Networking

CONTENTS

Scientific Program Day One | Tuesday, October 13

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

Discovery Chemistry	Discovery Biology	Preclinical	Translational Medicine	Clinical Lessons	Process & Analytical Development	Manufacturing & Supply Chain
Leveraging Novel Payload Mechanisms & Combinations to Combat Topo1 & MMAE Patient Resistance	Innovating Antibody Targeting & Engineering to Improve ADC Therapeutic Properties & Unlock New Treatment Indications	Upgrading the ADC Preclinical Toolbox to Reduce the Translational Mismatch Across Traditional & Novel ADCs	Optimizing ADC Patient Selection, Dosing & Trial Design to Set Up Early ADC Clinical Development for Success	Navigating the Crowded ADC Clinical Landscape to Achieve Differentiation & Maximize ADC Benefit to Patients	Enhancing ADC Quality Characterization & Process Control to Rapidly & Confidently Produce Complex Conjugates	Streamlining Internal & Outsourced ADC CMC Strategy to Efficiently Manufacture Cost-Effective ADCs at Scale
Striving for Innovative Payload Mechanisms to Advance Beyond the Topo1 Dogma	**Showcasing Bispecific ADCs to Overcome Tumor Heterogeneity with Favorable Safety Profiles**	**Incorporating *In Vivo* & *In Vitro* Workflows to Upgrade the ADC Preclinical Strategy Playbook**	**Contrasting Emerging Clinical Data & Preclinical Profiles: How Well do ADCs Translate to Patients?**	**The Next ADCs to Watch: Investigating Late-Stage Clinical Profiles of ADCs Delivering Patient Impact**	**Understanding Methods to Accelerate ADC Process & Characterization Without Impacting Quality**	**Exploring Best Practices to De-Risk Time & Cost-Sensitive ADC Manufacturing at Scale**
4 sessions	4 sessions	4 sessions	4 sessions	4 sessions	4 sessions	4 sessions
1:00 Lunch & Networking						
Employing Dual Payload Combinations to Circumvent Validated Payload Resistance	**Utilizing Bispecific ADCs to Expand a Narrow Range of Tumor Antigens Through Innovative Target Pairing**	**Signposting Preclinical Attributes to Set Up Novel ADC Mechanism Translation for Success**	**Leveraging ADC Biomarker Studies to Confidently Identity Patient Cut-Offs in Early ADC Development**	**Exploring ADC Sequencing & Combinations to Best Position ADCs Within Patient Therapy Regiments**	**Employing In-Depth Process Knowledge to Elevate ADC Production & Characterization**	**Assessing Selection Criteria to Identify Optimal ADC CDMO External Outsourcing Partners**
4 sessions	4 sessions	4 sessions	4 sessions	4 sessions	4 sessions	4 sessions
Presentation Preview:	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**
PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency • Highlighting rationale for developing the first reported degrader payloads versus a known oncology target in light of lack of efficacy from small molecule inhibitors • Laying out medicinal chemistry approaches to optimize PROTAC payload properties and exploring variety of conjugation approaches • Showcasing potent data generated in preclinical models and highlighting next steps in novel payload development **Alyn Davies**, Associate Director, Medicinal Chemistry, **AstraZeneca** NEW DATA	**The Emerging Wave of Bispecific ADCs: Breaking Down Design & Rationale for NEOK001 & NEOK002** • Delving into the IND-enabling profiles of bispecific ADCs NEOK001 and 002, emphasizing advantages over monospecific ADCs • Explaining the unique characteristics of NEOK001 targeting B7-H3+ROR1 including higher need for differentiation amongst B7-H3 ADC landscape • Breaking down early clinical development strategy and lessons learned from ongoing Phase I bispecific ADC trials **Patrick Zweidler-McKay**, Chief Medical Officer, **NEOK Bio** NEW COMPANY	**Beyond Topol & Tubulin: Advancing a First-in-Class Protein Alkylation Payload ADC IKS073** • Positioning protein alkylation as a differentiated and emerging modality within the evolving ADC payload landscape • Spotlighting the therapeutic potential of ProAlk™ payload through the preclinical profile of IKS073 targeting B7H3 in solid tumors • Laying out future development journey to progress the first ProAlk™ payload ADC to the clinic **Bob Lutz**, Chief Scientific Officer, **Iksuda Therapeutics**	**Spotlighting the Translational Profile of KIVU-107 to Strive for Kinder & Gentler ADC Therapies with Enhanced Therapeutic Index** • Laying out rationale for pursuing less toxic ADC development to enable higher dosing and expand ADC therapeutic index • Breaking down late-stage preclinical data of KIVU-107 in solid tumors to emphasize clinical opportunity and differentiation strategy • Unveiling the emerging clinical profile of KIVU-107 to investigate how well preclinical data translates to patient responses and lay out ongoing clinical development strategy **Mo Trikha**, Chief Executive Officer, **Kivu Biosciences** NEW DATA	**Contextualizing Clinical Success of Enhertu Combination to Secure First-Line Approval in HER2+ Metastatic Breast Cancer** • Envisioning potential for Enhertu to move from advanced to early oncology settings • Delving into the clinical data and first-line approval of Enhertu combination therapy in HER2+ metastatic breast cancer • Laying out rationale-driven research to identify combination partners complimentary to Enhertu mechanism **Ronald Fleming**, Executive Director, Clinical Development, **Daiichi Sankyo**	**Utilizing High Throughput Platforms & Automation Systems to Accelerate ADC Process Development Timelines** • Highlighting the necessity to leverage high throughput methods and automation to accelerate ADC process and analytical characterization • Laying out methodology is incorporate automation in PAT and increases platform throughput in ADC development • Understanding high throughput methods for process monitoring and real time bioconjugation approaches **Bingchuan Wei**, Senior Principal Scientist, CMC Team Lead, **Genentech**	**Breaking Down Case Study Learnings to Optimize Outsourced Bioconjugation & Minimize ADC Production Cost & Timelines** • Understanding the financial and timeline risks associated with outsourced ADC manufacturing • Contextualizing the significance of manufacturing partner selection with two early-stage conjugation program case studies • Laying out adaptations to pivot and resolve conjugation issues to ultimately successfully deliver ADC clinical material **Olga Paley**, Director & Head, US Downstream Process Development & Bioconjugation, **Takeda**
4:00 Afternoon Break & Scientific Poster Showcase						

CONTENTS

Scientific Program Day One | Tuesday, October 13

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

Demonstrating the Transformative Impact of ADCs to Reshape the Standard of Oncology Care & Deliver Improved Therapeutic Outcomes for Patients in Early-Line Settings

5:00 **Evaluating I-SPY2 Clinical Data & Toxicity Monitoring to Assess ADC Progression to Early-Stage Oncology Settings in TNBC & HER2+ Breast Cancer**

- Contextualizing I-SPY2 trials evaluating progression of ADCs to neoadjuvant and adjuvant settings in TNBC & HER2+ breast cancer
- Laying out clinical data generated to investigate early-line ADC progression, including recent clinical performance of Enhertu and Datroway
- Evaluating concerns with ADC-associated side effects, focusing on ILD monitoring, when considering advancement to neoadjuvant settings

Rita Nanda
Associate Professor, Medicine & Director, Breast Oncology, Section of Hematology/ Oncology
University of Chicago

5:30 **Expansion of ADC R&D & Manufacturing Capabilities in a Payload-Linker CDMO**

- Navigating buildout of ADC clinical manufacturing for diverse, highly potent payloads
- Exploring implementation of bioconjugation and bioanalytical capabilities within R&D
- Leveraging process and analytical characterization insights from commercial ADCs

Thomas Rohrer
Vice President, Bioconjugation
Veranova

6:00 **Setting the Scene for Novel Combination Partner Approaches for Vedotin-Based ADCs Including Padcev**

- Contextualizing the significance of combination approaches within the future of ADC patient impact in early-line oncology therapies
- Laying out the transformative clinical performance of Padcev-Keyruda combination including event free survival in MIBC
- Addressing the need and opportunity for novel combinations partners to enhance Padcev clinical impact

Sujata Narayanen
Vice President, Global Development Product Lead
Pfizer

6:30 **Chair's Closing Remarks**

Bob Lutz
Chief Scientific Officer
Iksuda Therapeutics

6:30 **Evening Drinks Reception**

Enjoy an informal end to the busiest conference day. With a backdrop of palm trees and the San Diego sunset, savor a drink of your choice, reconnect with peers, and meet fresh faces to break down your ADC learnings and objectives.

7:30 **End of Scientific Program Day One**

CONTENTS

Scientific Program Day Two | Wednesday, October 14

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

7:00 Check In, Morning Coffee & Light Refreshments

7:55 **Chair's Opening Remarks**

Mohit Trikha
Chief Executive Officer
Kivu Biosciences

Beyond the Topo1 Dogma: Unveiling Rationale-Driven Novel Payload Development & Properties to Herald ADCs with New Mechanisms & Improved Therapeutic Index

8:00 **Showcasing Non-Cytotoxic Payload Attributes, Selection & Performance to Enhance ADC Therapeutic Index Beyond the Cytotoxic Dogma**

- Understanding the importance of antibody epitope, influence of target isoforms and impact on internalization
- Unveiling detailed investigation of unique payloads to develop non-cytotoxic ADCs with improved therapeutic index beyond traditional conjugates
- Undergoing investigation of antigen internalization and tumor cell payload concentration to secure in-depth mechanistic understanding and benefit of antibody-mediated delivery
- Laying out takeaways for non-cytotoxic ADC development and applications to internal ADC development

Gail Lewis
Distinguished Scientist, Discovery Oncology
Genentech

8:30 **Unlocking the Full Potential of Antibody Conjugates: AJICAP® Technology for Precise DAR Control & Emerging Modality Applications**

- AJICAP® Conjugation: Leveraging site-specific technologies in next-generation ADCs to enhance clinically relevant biological properties through precise DAR control such as 1, 2, 4, 8 and higher
- AJICAP® Linker: Demonstrating a novel hydrophilic linker technology that enhances stability and enables versatile synthesis of ADCs with higher DAR numbers, even with highly hydrophilic payloads
- Application for new modality conjugates: Bispecific antibodies and antibody-oligonucleotide conjugates produced by fully chemical conjugation technology

Tomohiro Fuiji
Senior Researcher
Ajinomoto Bio-Pharma Services

9:00 **Drug Developer Presentation to be Released**

9:30 **Leveraging Bioconjugation Strategies to Enhance AOC CMC Processes**

- Navigating the nuances of oligonucleotide conjugate process development and understanding how to leverage physiochemical properties and chemistry aspects between different AOCs
- Comparing AOCs with classical ADCs: Explore payload complexity, impurity profiles, and essential analytical methods
- Assessing the evolving regulatory framework, impurity control, stability, immunogenicity and target product profiles
- Spotlighting real-world customer case studies that demonstrate a risk-managed approach to get to the clinic quicker

Petra Dieterich
Senior Vice President & Scientific Leader
Abzena

10:00 Morning Break & Scientific Poster Showcase

CONTENTS

Scientific Program Day Two | Wednesday, October 14

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

Discovery Chemistry	Discovery Biology	Preclinical	Translational Medicine	Clinical Lessons	Process & Analytical Development	Manufacturing & Supply Chain
Leveraging Novel Payload Mechanisms & Combinations to Combat Topo1 & MMAE Patient Resistance	Innovating Antibody Targeting & Engineering to Improve ADC Therapeutic Properties & Unlock New Treatment Indications	Upgrading the ADC Preclinical Toolbox to Reduce the Translational Mismatch Across Traditional & Novel ADCs	Optimizing ADC Patient Selection, Dosing & Trial Design to Set Up Early ADC Clinical Development for Success	Navigating the Crowded ADC Clinical Landscape to Achieve Differentiation & Maximize ADC Benefit to Patients	Enhancing ADC Quality Characterization & Process Control to Rapidly & Confidently Produce Complex Conjugates	Streamlining Internal & Outsourced ADC CMC Strategy to Efficiently Manufacture Cost-Effective ADCs at Scale
Evaluating ADC & AOC Development to Assess Therapeutic Potential in Autoimmune Indications	**Exploring Tumor Targets & Antibody Engineering to De-Risk Novel ADC Therapeutic Development**	**Undergoing Preclinical Investigation to Position ADC Development for Success in Crowded Clinical Indications**	**Highlighting Translational Profiles to Demonstrate Proof of Concept of Novel ADC Design & Mechanisms**	**Correlating ADC Design to Clinical Profiles: Is Innovation Leading to Meaning Patient Impact?**	**Assessing ADC Control Strategies to Confidently Undergo Enhanced Quality Characterization**	**Navigating the Nuances of Lyophilization to Improve Efficiency of ADC Drug Product Manufacturing**
4 sessions	4 sessions	4 sessions	4 sessions	4 sessions	4 sessions	4 sessions
1:00 Lunch & Networking						
Leveraging ADC Chemistry & Structure Insights to Develop Novel Conjugation Methods & Enhance ADC Design	**Pursuing Novel ADC Target Identification & Validation to Open Up New Indication Opportunities**	**Assessing Comprehensive ADC Preclinical Analysis to Prepare for Translation with Confidence**	**Tackling ADC Clinical Pharmacology to Approach ADC Dose Selection in First-in-Human Settings**	**Visualizing Clinical Strategies to Achieve Differentiation With First & Best-in-Class ADC Development**	**Employing Approaches to Improve Characterization & Production of Increasingly Complex Conjugates**	**Juggling ADC Supply Chain to Ensure Streamlined Manufacturing Under Tight Production Timelines**
3 sessions	3 sessions	3 sessions	3 sessions	3 sessions	3 sessions	3 sessions
Presentation Preview:	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**	**Presentation Preview:**
Exploring Development of E7766-Based STING ADCs: Influence of Payload Linker Attachment Site & Cleavage Kinetics • Delving into discovery of STING-agonist payload E7766, focusing on payload-linker attachment site • Investigating linker cleavage rate to enhance *in vitro* and *in vivo* antitumor activities • Showcasing *in vitro* and *in vivo* preclinical data of E7766-based STING ADCs **Dae-Shik Kim**, Senior Principal Scientist, **Eisai**	**Preclinical Evaluation of SLV-013: A Novel GPC1-Targeting ADC for the Treatment of Solid Tumors** • Providing the strategic rationale for targeting GPC-1, overall biology and comprehensive expression profiling across multiple cancer lineages and primary normal cells and tissues • Developing GPC-1 targeting ADCs, utilizing a proprietary hydrophilic and highly stable linker technology • Unveiling the preclinical characterization of SLV-013, including the cell binding, internalization, and *in vitro* and *in vivo* efficacy data **Hao Liu**, Senior Director, Drug Discovery & Cancer Biology, **Solve Therapeutics** **NEW COMPANY**	**Spotlighting Comprehensive Preclinical Development of Antifolate ADCs to Enter IND Phase for a Novel Drug-Linker Mechanism** • Presenting development of a novel antifolate drug-linker platform, leveraging a toxin class with a clinically validated mechanism of action • Exploring in vitro and in vivo preclinical development and physicochemical properties of frontrunner antifolate ADC program • Laying out pharmacology studies and dose range finding investigation in the lead up to antifolate ADC IND studies **Wim Dokter**, Chief Scientific Officer, **Byondis**	**Exploring the Preclinical Profile & IND Journey of Dual Payload ADC CAN016 for HER2 Refractory Patients** • Laying out CAN016 preclinical profile including monkey tox data supporting dual payload ADC IND approval • Contextualizing pre-IND filing approach as an emerging ADC modality, and strategy for HER2 refractory patient treatment • Highlighting ongoing first-in-human development of CAN016 and potential impact in HER2 refractory patients resistant to Enhertu **Henry Yu**, Chief Executive Officer, **CanWell Pharma** **NEW COMPANY**	**Reviewing the Intentional Design of Varseta-M, a Masked PROBODY® ADC for the Treatment of Colorectal Cancer** • Presenting Phase I clinical data of Varseta-M targeting EpCAM in colorectal cancer • Connecting masked ADC design correlation to compelling preclinical and clinical profile • Exploring Varseta-M future clinical development pathway with first-in-class ADC potential in late-late colorectal cancer **Sean McCarthy**, Chief Executive Officer, **CytomX Therapeutics**	**Assessing Purging Factors for Small Molecule Impurities During Post Conjugation Purification** • Breaking down survey results for solvent and reagent purging in post conjugation UF • Assessing general guidance for purge factors of small molecule impurities based on survey results • Putting forward proposals for nominal purging factors for reagents and solvents in regulatory context **Seb Caille**, Senior Director, AOC Process Development, **Avidity Biosciences, a Novartis Company**	**Characterizing Containment Bags as a Development Tool in ADC Lyophilization** • Evaluating effectiveness of containment bags in a development setting to enable ADC lyophilization for characterization and stability • Demonstrating ice slab sublimation testing as a tool to characterize heat and mass transfer effects of containment bags • Characterizing heat and mass transfer and load effects to improve the relevance of containment bags to process development **Aaron Pruett**, Principal Scientist, Drug Product Sciences, **MacroGenics** **NEW DATA**
3:30 Afternoon Break & Networking						

CONTENTS

Scientific Program Day Two | Wednesday, October 14

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

Delving Into ADC Performance in Crowded Clinical Indications With Approved ADC Therapies to Understand How Differences in Biconjugate Design & Clinical Strategy Correlates to Patient Impact

4:00 **Spotlighting the Clinical Performance of Izalontamab Brengitecan Bispecific ADC**

- Breaking down design and development of Iza-Bren, a EGFR/HER3 bispecific ADC, including advantages against traditional monospecific ADC therapies
- Evaluating Iza-Bren clinical profile based on recent clinical trials
- Laying out ongoing clinical development of Iza-Bren through bispecific ADC advantages and impactful clinical profile

Giorgia Vicentini
Vice President, Global Program Lead, Oncology
Bristol Myers Squibb

4:30 **Laying Out Advances in ADC Development & Manufacturing**

- Discussing tools used for the efficient and scalable manufacturing of the mAb intermediate, which serves as a key starting point for ADC conjugation
- Overcoming ADC mAb diversity challenges via AI-driven cell line design
- Explaining operator safety risk-mitigation enabled by agnostic, automated solutions

Sean Muthian
Chief Technology & Strategy Officer
Cytiva

5:00 **Highlighting the Clinical Promise from Phase I/IIa Development of TUB-040 in Platinum Resistant Ovarian Cancer**

- Explaining TUB-040 ADC design innovation across payload, conjugation and validated NaPi2b target
- Detailing proof-of-concept data and strong ORR from the emerging clinical profile of TUB-040
- Contrasting clinical performance to preclinical data to assess how well TUB-040 innovation has been translated into patient studies
- Highlighting the clinical development strategy and potential therapeutic impact of TUB-040 in PROC with an existing approved ADC therapy

Dominik Schumacher
Chief Executive Officer
Tubulis

5:30 **Chair's Closing Remarks**

Mohit Trikha
Chief Executive Officer
Kivu Biosciences

6.00 **13th World ADC Awards**

At the end of the main conference days, join the community for an unforgettable gala honoring the best programs, companies and individuals in the ADC field. Across multiple award categories, this is your opportunity to reflect and recognize the long-term contributors, novel and innovative programs, and upcoming pioneers who have gone above and beyond to deliver the continued success and future direction of the field.

13th ANNUAL WORLD adc AWARDS

8:00 **End of Scientific Program Day Two**

CONTENTS

Post-Conference Workshop Day | Thursday, October 15

8:00 Check In, Morning Coffee & Light Refreshments

Workshop A
Tailored to Discovery Chemistry & Discovery Biology Content

9:00 Assessing the Development & Emerging Potential of Immune-Stimulating & Immune-Suppressing ADCs in Oncology & Beyond

Immune-modulating ADCs represent a class of non-cytotoxic payloads receiving increased attention as the field looks to diversify ADC mechanisms beyond classical Topo1 and MMAE therapies.

Attend this workshop to cover the history of immune-stimulating therapies and the progress being made to make effective ADC payloads, alongside the emerging development of immune-modulating ADCs expanding applications outside of oncology.

Workshop highlights include:

- Overviewing the ISAC field to contextualize clinical learnings and the opportunity of ISACs as an alternative, non-cytotoxic ADC mechanisms
- Delving into TLR7/8 and STING agonist development to understand which immune-stimulating molecules make effective ADC payloads
- Assessing the emergence of immune-suppressing ADCs leveraging glucocorticoid mechanisms for ISAC applications outside of oncology

L. Nathan Tumey, Associate Professor, **Binghampton University**

Workshop B
Tailored to Preclinical & Translational Medicine Content

9:00 Translating ADC Tolerability: Deep-Diving Into Toxicity Characterization & Preclinical Strategy to Better Predict ADC Clinical Safety Profiles

Even with 2026 seeing ADCs continue to rival oncology standard of care performance, translation of ADC toxicity profiles to the clinic remains the largest hurdle to widen ADC therapeutic index and accomplish widespread impact for patients in need.

Led by long-standing ADC toxicity experts, join your peers to understand ADC class effect toxicities and best leverage preclinical tools and historical learnings to effectively characterize safety profiles and predict ADC tolerability in the clinic.

Workshop highlights include:

- Discussing ADC class effect toxicities observed in the clinic across ocular toxicity, ILD, neutropenia and beyond
- Delving into deployment and utilization of *in vivo* and *in vitro* models to improve prediction of clinical toxicity profiles
- Breaking down lessons learned from successful and failed historical ADC translation to inform design, engineering and characterization of better ADCs with wider therapeutic index

Rakesh Dixit, Chief Executive Officer, **Bionavigen Oncology**

Melissa Schutten, Executive Director, Nonclinical Sciences & Pathology, **Gilead Sciences**

Workshop C
Tailored to Translational Medicine & Clinical Lessons Content

9:00 Connecting ADC Design & Component Contribution to Clinical Safety & Efficacy: What Makes a Clinically Impactful ADC?

As an increasingly diverse array of ADCs containing different payloads and linkers are developed to tackle different tumor targets, understanding how bioconjugate design contributes and accumulates to performance in the clinic is vital to set up your therapy for success.

Take part in this workshop exploring recent case-study examples to contextualize and understand the performance of different ADC designs to understand what really makes a clinically effective ADC.

Workshop highlights include:

- Accurately correlating and characterizing antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
- Delving into ADC clinical case studies to evaluate differentiated design impact on safety and efficacy profiles to understand what makes a clinically effective ADC
- Finding the right match: Optimizing ADC design to improve payload target pairing

Jutta Deckert, Vice President, R&D, **Iksuda Therapeutics**

Bob Lutz, Chief Scientific Officer, **Iksuda Therapeutics**

Workshop D
Tailored to Clinical Lessons & Process & Analytical Development Content

9:00 Exploring the Depths & Breadth of ADC Bioanalysis to Ensure In-Depth PK/PD Analysis & Best Inform Clinical Strategy

Properly understanding ADC PK/PD and *in vivo* stability is crucial to best inform clinical performance and trial design.

Don't miss this session exploring bioanalytical strategy across development phases, insights into LC-MS method development, and in vivo biotransformation impacting PK/PD and stability properties to understand how to efficiently leverage bioanalytical technologies to best characterize your ADC clinical material.

Workshop highlights include:

- Explaining the significance of ADC bioanalysis across reagent characterization and immunogenicity in early-stage ADC development
- Contextualizing bioanalytical analysis to understand clinical PK/PD consequences and impact on clinical development strategy
- Laying out regulatory expectations and emerging technologies for comprehensive ADC bioanalytical workflows across development phases

Sophia Xu, Director, Clinical Bioanalysis, **Daiichi Sankyo**

Workshop E
Tailored to Manufacturing & Supply Chain Content

9:00 Deep Diving Into CMC Best Practices to Ensure Stakeholder Alliance to Optimize ADC Production & Regulatory CMC Strategy

Selecting and maintaining strong relationships with CDMO and regulator stakeholders is vital to navigate ADC manufacturing and supply chain in a timely, cost-effective and regulatory compliant manner to bring more accessible ADC therapies to patients in need.

Join this strategy-led workshop session to troubleshoot and optimize CMC stakeholder relationships to ensure ADC GMP quality and best set up regulatory submissions for success.

Workshop highlights include:

- Debating and navigating differences in opinion between industry and outsourcing partners at different stages of ADC manufacturing
- Understanding best strategies to optimize manufacturing stakeholder relationships and ensure ADC quality under GMP requirements
- Assessing best approaches for ADC regulatory submissions with discussion of science-based justifications to support alternative ADC control strategies

Herbert Ogutu, Senior Manager, Contract Development & Manufacturing, **Amgen**

Jonathan Harris, Executive Director, Regulatory Affairs CMC, **Exelixis**

CONTENTS

Post-Conference Workshop Day | Thursday, October 15

17th ANNUAL WORLD adc SAN DIEGO 2026
October 12-15 2026

12:00 Lunch & Networking

Workshop F
Tailored to Discovery Chemistry & Discovery Biology Content

1:00 Encompassing the Breadth of Conjugation Approaches to Optimize Bioconjugate Design & Performance Across Traditional, Dual Payload ADCs & Beyond

Understanding the advancements at the forefront of conjugation chemistries are vital to optimize ADC design, DAR and therapeutic properties from the get-go.

Join this workshop to secure your understanding of fundamental principles of ADC conjugation and assess the pros and cons of next-generation technologies.

Workshop highlights include:

- Delving into case studies of stochastic and site-specific conjugation to understand ADC design principles and connection to therapeutic profile
- Exploring state-of-the-art and niche conjugation approaches across click chemistry, enzymatic, chemical and antibody engineering conjugation to push the boundaries of novel ADC design
- Breaking down dual payload conjugation strategies as the field increasingly focuses on multi-mechanism approaches
- Beyond ADCs: Understanding additional nuances beyond traditional conjugation across AOCs, PDCs and beyond

Brian Mendelsohn, Independent Consultant

Workshop G
Tailored to Preclinical Content

1:00 Balancing the Pace of Preclinical Development & Confident *In Vivo* Analysis to Optimize ADC Speed to Clinic

Despite ADC's raging success as oncology therapies, translational barriers still plague bioconjugate development, with pressure to enter the clinic quickly but preclinical activity not matching early clinical readouts.

As the field turns its attention to advance more non-traditional ADC translation, join this workshop to break down best strategy to balance depth of characterization against time, contextualized with reverse translational learnings to better advance ADCs to the clinic with confidence.

Workshop highlights include:

- Leveraging reverse translation insights to streamline ADC preclinical efficacy assessment through intentional deployment of CDX and PDX models
- Debating optimized strategies to balance preclinical characterization against time and cost to best advance ADCs to the clinic with confidence
- Conducting translational studies to identify biomarkers for ADC sensitivity and resistance

Workshop Leader to be Confirmed

Workshop H
Tailored to Translational Medicine & Clinical Lessons Content

1:00 Breaking Down Trends & Strategies to Maximize ADC Clinical Impact in an Increasingly Busy Oncology Landscape

With more ADCs entering the clinic than ever before, it has never been more important to optimize clinical strategies to demonstrate differentiation and benefit oncology patients.

Attend this session to follow ADC clinical trends across development phases from early to late-stage, and contextualize evolving strategies to stand out from the crowd and maximize differentiation opportunity in crowded oncology indications.

Workshop highlights include:

- Breaking down the ADC clinical development trends in an increasingly busy oncology treatment landscape: How will ADCs fit into future patient therapy regiments?
- Evolving strategies to unlock clinical benefit across combination and sequencing approaches as more ADCs are approved, particularly into front-line patient therapies
- Finding the right patient for the right ADC: Evaluating when and how to implement patient cut-off criteria

Jian Chen, Director, Translational Research & Preclinical Development, **BioAtla**

Workshop I
Tailored to Process & Analytical Development Content

1:00 Beyond Traditional ADCs: Breaking Down Control Strategies for Non-Cytotoxic Bioconjugate Modalities

As the ADC field shifts to novel payload mechanisms and more complex ADC design to deliver meaningful patient impact, quality characterization and control strategies need to be adapted and updated to keep up with the rate of ADC innovation.

Join this workshop led by big pharma leaders and members of the IQ consortium to investigate best approaches for non-cytotoxic and non-traditional ADC control strategies.

Workshop highlights include:

- Defining the control strategy for non-cytotoxic bioconjugates including AOCs and antibody–peptide conjugates across CQAs, release testing, and stability
- Comparing control strategies for non-cytotoxic versus cytotoxic bioconjugates, highlighting differences in potency assays, impurity profiles, and safety controls
- Applying patient centric quality control to non-cytotoxic bioconjugates by linking specifications to clinical relevance

Hui Wei, Chair, Biologics Specification Committee & Head, Biologics Analytical Technical Integration, **Bristol Myers Squibb**

Matt Lorenz, Director, Bio Pivotal Analytical Development, **Gilead Sciences**

Sunnie Kim, Associate Director, Analytical Sciences, **Regeneron**

Wenhua Wang, Fellow Scientist, **Regeneron**

Workshop J
Tailored to Manufacturing & Supply Chain Content

1:00 CMC Fundamentals from Gene & Payload to IND: Exploring Typical Workplans, Best Practices, Common Pitfalls, & Tips to Manage a Complex Supply Chain

As more companies emerge and pivot to enter the field of ADC development, understanding analytical and CMC principles, requirements, and timelines is vital to advance to IND and stay competitive in a busy biopharma ecosystem.

Designed for ADC biotech C-level, CMC, analytical and quality leaders currently in discovery stage, don't miss this workshop to learn the CMC roadmap and accelerate your ADC development from gene to IND.

Workshop highlights include:

- Outlining and optimizing the CMC timeline to achieve clinical supply readiness and enable patient dosing immediately upon IND allowed-to-proceed
- Navigating the process development activities and delving into cell line development, biologic design, linker-payload and conjugation
- Detailing the core principles of analytical development and specifications

Sonia Appel, Founder & Principal Consultant, **Alismere**

Sanjeevani Ghone, Founder & Consultant, **SACHEMIE Consultancy**

Ruby Casareno, Biologics CMC Consultant, **Self-Employed**

4:00 End of Post-Conference Workshop Day

CONTENTS

Partnership Opportunities

As ADCs continue to deliver clinical impact and the industry invests in novel mechanisms and design to differentiate future performance, **specialized and impactful ADC solutions are in high demand to accelerate biopharma's need to develop, characterize and produce the next wave of bioconjugates**.

With the bar raised to develop a successful ADC, **service providers also need to upgrade their capabilities and solutions to stay competitive in an increasingly busy and competitive ADC ecosystem**. This includes next-generation payload-linker and conjugation platforms, enhanced preclinical tools, biomarker and clinical development expertise, and upgraded manufacturing expertise adaptable to varied bioconjugate design.

Get in touch now to understand how **World ADC San Diego** can help deliver your 2026 ADC commercial objectives, and unlock preferential speaking, exhibition, networking and branding positions while optimal places remain.

COMPANY TYPE BREAKDOWN*

- **215 Drug Developer Companies**
- **23 Leading Oncology Pharma**
- **81 US ADC Biotechs**
- **70% of Returning Companies Matched Or Increased Attendance**
- **112 New Companies Year-on-Year**

*ADC biotechs identified according to companies identified by Beacon by Hanson Wade

ATTENDEE SENIORITY**



- **C-Level: 14%**
- **VP & Director: 51%**
- **Management: 20%**
- **Scientist, Researcher & Other: 15%**

** Statistics taken from 16th World ADC San Diego

Partnership Opportunities Include:

- **Data-driven case study presentations** to elevate your services and technical expertise above your competitors within a crowded market
- **Exhibition booths** to better support lead generation, business development goals and relationship management
- **Private networking** for exclusive time with your core target audience to support generation of high-quality leads
- **Onsite and web branding** to increase your company's visibility and brand to build a greater reputation within ADC development

Want to elevate your presence and impact at World ADC San Diego? Explore bespoke branding, networking, and hosting partnership opportunities with the venue-specific Creative Branding Opportunities Brochure

Download Your Free Copy

Partnerships Team:

Nicholas Ramovic

George Shrimpton

Eleni Topollaj

+415 735 3289 **sponsor@hansonwade.com**

REGISTER BEFORE FRIDAY, JUNE 5 & SAVE UP TO $700

CONTENTS

REGISTER NOW

2026 Senior Partners

Lead Partner: WuXi XDC

WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.

www.wuxixdc.com

Senior Partner: Abzena

Abzena is the leading end-to-end bioconjugate (ADCs, AOCs, RDCs) and complex biologics CDMO + CRO. From discovery through commercial, we support customers with fully integrated programs or individual services that de-risk and streamline the development of new medicines. With over two decades of experience, 2000+ conjugates developed and over 200+ cell lines developed, we have the expertise and technical know-how to rapidly progress your biopharmaceutical to IND and beyond. And with footholds in San Diego, CA, Bristol, PA, and Cambridge, UK, we offer a simplified and secured supply chain.

www.abzena.com

Senior Partner: Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill f inish, including cytotoxics. As a global CDMO, they provide the adaptive solutions, responsive service, trusted partnership and peace of mind you've come to rely on.

www.ajibio-pharma.com

Senior Partner: Cytiva

Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics—from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™.

www.cytiva.com

Senior Partner: Veranova

Veranova is a global leader in the development and manufacturing of specialist and complex active pharmaceutical ingredients for pharma and biotech customers. Veranova's global team of highly skilled process chemists and analytical scientists possess over a decade of experience developing and scaling up processes for linking small molecule payloads to polymers in support of antibody drug conjugates and polymer drug conjugates.

www.veranova.com

2026 Partners

Program Partners

Altruist 夏尔巴生物 · AsymBio · axplora Reliable partner. Agile explorer · BIOCYTOGEN · BioDlink · BIO-REINNOVATION 佰茵生物 · CATENABIO · ChemExpress

defence THERAPEUTICS · GENOVIS · GLYKOS · HUB ORGANOIDS · is now part of MilliporeSigma · invenra · XLIDE · LigaChemBio

Lonza · LOTTE BIOLOGICS · MabPlex · MilliporeSigma · natera · NONA BIOSCIENCES · 康龙化成 PHARMARON · Piramal Pharma Solutions · proveo A division of Cerbios-Pharma SA · SAMSUNG BIOLOGICS · SARTORIUS

Simtra BioPharma Solutions · SK pharmteco · Sterling · SYGNATURE DISCOVERY · TFMeds Excelling in ADC and ARC · TEMPUS · Trinity Consultants SafeBridge · Tripartite Therapeutics · turbine · XCELLON · Zencore Biologics

Exhibition Partners

abbvie · AVID BIOSERVICES · BAUSCH+STRÖBEL · BioAgilytix · BioDuro · BIOINTRON · Bionova Scientific · BIOVECTRA A part of Agilent · CERTIS ONCOLOGY INTELLIGENCE

ChemPartner · Cohance · curia · eurofins CDMO · eurofins BioPharma Product Testing · FARMHISPANIA GROUP · GLYCOGENE · heidolph AN ATS COMPANY · HUIDA BIOTECH 诺达生物 · ICE Innovative CRO+Explorer ICE Bioscience

ILC DOVER An Ingersoll Rand Business · INNOSTAR · KYONGBO · PORTON · Project pharmaceutics · Promega · Sharp · SynOligo BIOTECHNOLOGIES · TAPI TECHNOLOGY & API SERVICES · WILMINGTON PHARMATECH · 药明康德 WuXi AppTec

Event Partners

BSP PHARMACEUTICALS · Catalent · CHAMPIONS ONCOLOGY · Creative Biolabs®

CONTENTS

Ready to Register?

3 Easy Ways To Book

www.worldadc-usa.com/take-part/register

register@hansonwade.com

US +1 415 735 3289

Team Discounts

Get value for money using special team discounts:

- **20% discount – 7+ delegates**
- **15% discount – 5+ delegates**
- **10% discount – 3+ delegates**

Bring Your Team

Please note that discounts are only valid when 3 or more delegates from one company register at the same time. Not for profit rates are available - email adc@hansonwade.com

Venue

Town & Country San Diego

500 Hotel Circle, North San Diego, CA, 92108

www.towncountry.com

Terms & Conditions

Full payment is due on registration.

Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

Innovate **Collaborate** **Redefine Oncology Therapeutic Patient Impact**

Drug Developer & Platform Tech Pricing*	Register by Friday, June 5	On the Door Price
Conference + Workshop Day & Seminar Day (Full 4 Day Access Pass)	$4,697 **(Save $600)**	$5,297
Conference + Seminar Day OR **Conference + Workshop Day** (3 Day Pass)	$3,648 **(Save $600)**	$4,248
Conference Only (2 Day Pass)	$2,599 **(Save $600)**	$3,199

*To qualify for the drug developer rate, your company must have a public drug pipeline, and must not provide pay-for services to any other company.

Academic Pricing**	Register by Friday, June 5	On the Door Price
Conference + Workshop Day & Seminar Day (Full 4 Day Access Pass)	$4,195 **(Save $500)**	$4,695
Conference + Seminar Day OR **Conference + Workshop Day** (3 Day Pass)	$3,197 **(Save $500)**	$3,697
Conference Only (2 Day Pass)	$2,199 **(Save $500)**	$2,699

**To qualify for the academic rate, you must be a full-time academic. Please email us or visit the website for full pricing options

Service Provider Pricing	Register by Friday, June 5	On the Door Price
Conference + Workshop Day & Seminar Day (Full 4 Day Access Pass)	$6,995 **(Save $700)**	$7,695
Conference + Seminar Day OR **Conference + Workshop Day** (3 Day Pass)	$5,597 **(Save $700)**	$6,297
Conference Only (2 Day Pass)	$4,199 **(Save $700)**	$4,899

REGISTER BEFORE FRIDAY, JUNE 5 & SAVE UP TO $700

CONTENTS

REGISTER NOW

hansonwade